A31.2 Disseminated mycobacterium avium-intracellulare complex (DMAC)

Name of the Condition

• Disseminated mycobacterium avium-intracellulare complex (DMAC)

Summary

Disseminated mycobacterium avium-intracellulare complex (DMAC) is a systemic infection caused by mycobacteria from the Mycobacterium avium-intracellulare complex (MAC). This condition involves widespread infection, typically affecting multiple organs, and is often associated with immunocompromised states. DMAC is a subset of nontuberculous mycobacterial (NTM) infections and can lead to significant morbidity if not managed appropriately.

Causes

DMAC is caused by the Mycobacterium avium-intracellulare complex, a group of environmental mycobacteria found in water, soil, and biofilms. Transmission occurs through inhalation of contaminated aerosols or ingestion of contaminated water, leading to systemic spread in susceptible individuals. The bacteria can disseminate beyond the initial site of infection, affecting organs such as the lungs, liver, spleen, and bone marrow.

Risk Factors

• Weakened immune system: Conditions like advanced HIV/AIDS, immunosuppressive therapies, or chronic diseases (e.g., cancer) increase susceptibility.
• Low CD4+ T-cell count: Particularly in HIV-positive individuals, a CD4 count below 50 cells/µL is a strong risk factor.
• Environmental exposure: Prolonged contact with contaminated water sources or soil may elevate risk in immunocompromised persons.

Symptoms

• Persistent fever, night sweats, and weight loss
• Fatigue and weakness
• Abdominal pain or hepatosplenomegaly (enlarged liver/spleen)
• Chronic diarrhea or malabsorption
• Anemia or pancytopenia (low blood cell counts)
• Respiratory symptoms (e.g., cough, dyspnea) if lungs are involved

Diagnosis

Diagnosis requires a combination of clinical evaluation, imaging, and laboratory testing. Blood cultures or tissue biopsies (e.g., bone marrow, lymph node) are used to identify M. avium-intracellulare complex. Imaging (e.g., CT scans) may reveal organ involvement, while PCR or acid-fast bacilli (AFB) staining can confirm mycobacterial presence. CD4 counts and immune status are also assessed to guide management.

Treatment Options

Treatment involves prolonged multidrug antibiotic therapy, typically including macrolides (e.g., clarithromycin or azithromycin) combined with ethambutol and rifabutin. Adjunctive therapies may address symptoms or organ-specific complications. In HIV-positive patients, antiretroviral therapy (ART) is critical to restore immune function and prevent recurrence.

Prognosis and Follow-Up

Prognosis depends on immune status and timely treatment. With appropriate therapy, many patients achieve clinical improvement, but relapse can occur if immunity remains compromised. Follow-up includes monitoring treatment response (e.g., symptom resolution, lab values) and ongoing immune function assessment. Lifelong suppressive therapy may be necessary in severely immunocompromised individuals.

Complications

• Severe malnutrition or cachexia
• Organ dysfunction (e.g., liver failure, respiratory failure)
• Recurrent infections due to persistent immunosuppression
• Treatment-related toxicity (e.g., drug-induced hepatitis)

Lifestyle & Prevention

• Avoid exposure to contaminated water or soil, especially in immunocompromised states.
• Ensure safe drinking water and proper wound care to reduce infection risk.
• Maintain adherence to prescribed therapies, including ART in HIV-positive patients.
• Regular monitoring of immune status (e.g., CD4 counts) to detect early signs of recurrence.

When to Seek Professional Help

Seek immediate care for persistent fever, unexplained weight loss, or worsening respiratory symptoms, particularly if you have a weakened immune system. Prompt evaluation is critical to prevent systemic spread and complications.

Tips for Medical Coders

Document the presence of disseminated infection, organ involvement, and underlying immunocompromising conditions (e.g., HIV/AIDS) to support code assignment. Ensure lab results (e.g., positive cultures for M. avium-intracellulare) and clinical findings are clearly recorded. For HIV-positive patients, note CD4 counts and ART status, as these impact coding and reimbursement considerations.